Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and endocrine therapy are the gold standards for systemic therapy for patients with hormone-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer. Following progression, no prospective randomized data exi...

Full description

Bibliographic Details

Published in:	Medicina
Main Authors:	Ioana-Miruna Stanciu, Cristina Florina Pirlog, Andrei-Wilhelm Anghel, Andreea Ioana Parosanu, Cristina Mihaela Olaru, Cristina Orlov-Slavu, Ion Cristian Iaciu, Ana Maria Popa, Radu Constantin Vrabie, Cornelia Nitipir
Format:	Article
Language:	English
Published:	MDPI AG 2023-04-01
Subjects:	CDK4/6 inhibitors CDK4/6 rechallenge CDK4/6 toxicity ribociclib abemaciclib
Online Access:	https://www.mdpi.com/1648-9144/59/4/696